Real-world Evaluation of Qingxin Zishen Decoction on Ovarian Reserve Function Clinical Efficacy in Patients With Decreased

Real-world Evaluation of the Clinical Efficacy of Qingxin Zishen Decoction in Patients With Reduced Ovarian Reserve

A prospective cohort study evaluated the clinical efficacy of Qingxin Zishen Decoction

1.AMH AMH <1.1ng/ml 2.AFC: AFC <5~7 ovaries on both sides 3.Basic FSH: Basal FSH for two consecutive menstrual cycles ≥10 IU/L 4.Aged between 25 and 45 years old, female.

1. Those with reduced ovarian function caused by ovarian or uterine surgery, radiotherapy and chemotherapy;
2. Liver function (AST or ALT) and renal function (BUN or Ccr) are greater than 2 times the normal value;
3. Patients with a history of mental illness or legal disability
4. Those who have used endocrine-affecting drugs within 3 months before the study, estrogen, progesterone or related compound preparations, oral contraceptive pills, Chinese medicines or Chinese patent medicines related to the treatment of premature ovarian failure. Our hospital's preparations include Wu Turtle Rejuvenation Oral Liquid and Kuntai Capsules.
5. Patients with unexplained irregular vaginal bleeding
6. Patients who are participating in clinical trials of other drugs
7. For women who want to have children, those whose spouse's semen test fails to meet the standard will be excluded.